AstraZeneca Pharma India Limited ASTRAZEN NSEPHARMA
Company Overview
AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, markets, and trades in pharmaceutical products in India and internationally. It provides medicines for cardiovascular, renal, metabolic, and immunological conditions; oncology medicines under the TAGRISSO, Lynparza, ENHERTU, IMFINZI, and Zoladex brand names; rare diseases medicines under the Koselugo brand name; and respiratory medicines under the Symbicort and Fasenra brand names. The company also offers medicines for diabetes; and clinical trial services. The company has a strategic collaboration with Leica Biosystems and Daiichi Sankyo Company, Limited for the development of an immunohistochemistry assay and an image analysis algorithm for the TROP2 NMR biomarker in non-small cell lung cancer. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.
Why Investors Should Care
Generates a return on equity of 21.5%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 25.5%.
Net profit has compounded at 23.6% per year over the last five years.
Revenue has grown at a 31.3% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.13.
Recent Developments
- Mar 2026 Revenue of ₹2,272.58 Cr (+32.6% YoY); net profit ₹187.52 Cr.
- Trailing 12 Months Year-on-year growth — revenue +32.6%, earnings +62.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 31.3%, profit CAGR 23.6%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 31.34% |
| 1 Year: | 32.64% |
Compounded Profit Growth
| 5 Years: | 23.61% |
| 1 Year: | 62.02% |
Stock Price Performance
| 1 Year: | -19.56% |
| 6 Months: | -19.87% |
| 3 Months: | -17.48% |
| 1 Month: | -14.01% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)23.41 · Oversold
P/E of 92.59 is above the sector median of 41.64 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 21.5%.
- Healthy ROCE of 25.5%.
- Compounding revenue at 31.3% over 5 years.
- Profit CAGR of 23.6% over 5 years.
CONS
- Trading at a high P/E of 92.6.
- Trading 29.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
- RSI at 23 suggests oversold conditions.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ASTRAZEN AstraZeneca Pharma India Limited NSEPHARMA | 6,944.00 | 92.59 | ₹17,360.00 Cr | 0.45% | 25.48% | 21.49% | 31.34% | 23.61% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,899.00 | 39.73 | ₹4.56 L Cr | 0.82% | 17.94% | 13.74% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 9,100.00 | 94.06 | ₹2.42 L Cr | 0.36% | 18.96% | 15.32% | 10.98% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,857.00 | 75.99 | ₹1.64 L Cr | 0.77% | 9.05% | 25.79% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,650.00 | 64.10 | ₹1.24 L Cr | 0.22% | 19.20% | 20.48% | 14.85% | 33.34% |
| 6 | LENSKART LENSKART SOLUTIONS LTD NIFTY_MIDNSEPHARMA | 684.90 | 236.17 | ₹1.19 L Cr | 0.00% | 7.21% | 5.65% | 35.38% | 66.99% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,120.00 | 22.36 | ₹1.13 L Cr | 0.09% | 19.04% | 18.59% | 16.55% | 36.99% |
| 8 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,385.00 | 28.85 | ₹1.12 L Cr | 0.88% | 14.86% | 11.27% | 7.23% | 11.45% |
| 9 | LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA | 1,840.00 | 111.85 | ₹99,333.61 Cr | 0.13% | 19.53% | 16.77% | 3.77% | 4.00% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 480.48 Cr | 526.31 Cr | 559.09 Cr | 611.57 Cr | 578.61 Cr |
| Cost of Revenue | - | 259.61 Cr | 295.41 Cr | 324.49 Cr | 366.39 Cr | 394.25 Cr |
| Gross Profit | - | 220.87 Cr | 230.90 Cr | 234.60 Cr | 245.18 Cr | 184.36 Cr |
| Operating Expenses | - | 152.19 Cr | 166.36 Cr | 161.99 Cr | 204.19 Cr | 129.05 Cr |
| Operating Income | - | 68.68 Cr | 64.54 Cr | 72.61 Cr | 40.99 Cr | 55.31 Cr |
| EBITDA | - | 96.84 Cr | 91.99 Cr | 76.06 Cr | 51.44 Cr | 65.78 Cr |
| Interest Expense | - | 68.00 L | 72.00 L | 67.00 L | 1.06 Cr | 2.04 Cr |
| Pretax Income | - | 78.47 Cr | 74.70 Cr | 72.82 Cr | 46.54 Cr | 58.14 Cr |
| Tax Provision | - | 20.22 Cr | 18.87 Cr | 18.60 Cr | 13.95 Cr | 13.26 Cr |
| Net Income | - | 58.25 Cr | 55.83 Cr | 54.22 Cr | 32.59 Cr | 44.88 Cr |
| Diluted EPS | - | 23.30 | 22.33 | 21.69 | 13.04 | 17.95 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 1,002.97 Cr | 1,295.53 Cr | 1,713.29 Cr | 2,272.58 Cr |
| Cost of Revenue | - | 425.26 Cr | 673.26 Cr | 1,000.58 Cr | 1,488.69 Cr |
| Gross Profit | - | 577.71 Cr | 622.27 Cr | 712.71 Cr | 783.89 Cr |
| Operating Expenses | - | 428.82 Cr | 450.84 Cr | 497.90 Cr | 549.25 Cr |
| Operating Income | - | 148.89 Cr | 171.43 Cr | 214.81 Cr | 234.64 Cr |
| EBITDA | - | 150.99 Cr | 235.68 Cr | 197.81 Cr | 285.27 Cr |
| Interest Expense | - | 63.00 L | 1.20 Cr | 1.46 Cr | 4.49 Cr |
| Pretax Income | - | 134.10 Cr | 219.54 Cr | 156.36 Cr | 252.20 Cr |
| Tax Provision | - | 34.81 Cr | 58.03 Cr | 40.62 Cr | 64.68 Cr |
| Net Income | - | 99.29 Cr | 161.51 Cr | 115.74 Cr | 187.52 Cr |
| Diluted EPS | - | 39.70 | 64.60 | 46.30 | 75.00 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 984.87 Cr | 1,078.03 Cr | 1,518.12 Cr | 1,989.10 Cr |
| Current Assets | - | 835.47 Cr | 932.71 Cr | 1,342.35 Cr | 1,739.93 Cr |
| Cash & Equivalents | - | 500.34 Cr | 505.57 Cr | 536.14 Cr | 447.72 Cr |
| Inventory | - | 190.21 Cr | 227.88 Cr | 548.50 Cr | 1,027.33 Cr |
| Receivables | - | 107.52 Cr | 153.13 Cr | 184.88 Cr | 213.68 Cr |
| Total Liabilities | - | 396.18 Cr | 366.11 Cr | 747.77 Cr | 1,116.31 Cr |
| Current Liabilities | - | 383.93 Cr | 357.12 Cr | 703.00 Cr | 981.81 Cr |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 7.21 Cr | 4.59 Cr | 35.73 Cr | 110.66 Cr |
| Total Equity | - | 588.69 Cr | 711.92 Cr | 770.35 Cr | 872.79 Cr |
| Shares Outstanding | - | 2.50 Cr | 2.50 Cr | 2.50 Cr | 2.50 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 58.29 Cr | 27.87 Cr | 65.36 Cr | -15.14 Cr |
| Investing Cash Flow | - | 18.11 Cr | 21.74 Cr | 30.80 Cr | 18.69 Cr |
| Financing Cash Flow | - | -24.48 Cr | -44.38 Cr | -65.59 Cr | -91.97 Cr |
| Capital Expenditure | - | -8.52 Cr | -10.76 Cr | -1.75 Cr | -3.61 Cr |
| Free Cash Flow | - | 49.77 Cr | 17.11 Cr | 63.61 Cr | -18.75 Cr |
| Net Change in Cash | - | 51.92 Cr | 5.23 Cr | 30.57 Cr | -88.42 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 57.6% | 48.0% | 41.6% | 34.5% |
| Operating Margin % | - | 14.8% | 13.2% | 12.5% | 10.3% |
| Net Margin % | - | 9.9% | 12.5% | 6.8% | 8.3% |
| ROE % | - | 16.9% | 22.7% | 15.0% | 21.5% |
| ROCE % | - | 24.8% | 23.8% | 26.4% | 23.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ASTRAZEN
AZN Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiT0FVX3lxTFBzT19oTlp3dUtJVUUyZVlhbFJxdHJLdWp1VU9PdGRZTS1KYzRvNVN3VmZXZVVZYmNvTW1iWW5pc0tQazFVbW8zYzZUWkZVSDA?oc=5" target="_blank">AZN Stock Quote Price and Forecast</a> <font colo…
Top Stock Reports for AMD, Costco & AstraZeneca - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOb1ZwZDZCMFFYdXRZWkNtUUg4VzlQOVdSNXBCUWV0eVdtUHBOZ2dOeHZyQ3dyX0ppb2N5MzhKMFotYm8teWtoeFlISWEzdU1qaXNTUEp6UE9TQUdRWHpYVXRDcW5Zdy1oVEl6MkdqSVlRdEk1ejQ1ZWoxdmxlN1ItUnEzWG5nRWkxZUk5LX…
AstraZeneca (AZN) Stock Forecast and Price Target 2026 $AZN - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE9fVGxaRkhsb1BzMVhsRkt2NGF0WWJ4TGJJMXMxczZvTjljcHVCbjB4aWtNbjY1MDJMWE5qUl81Z2dWaGJidHJQSExaQ3lVVi1ZRUdJYUx6ZXBnNW5zN3M1Vw?oc=5" target="_blank">AstraZeneca (AZN) Stock Forecast and …
Deal or No Deal, AstraZeneca Stock Is a Bargain - WSJ
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxQVjYyYlNzdWlTM3E3dU96dVZ6cVdxaXhoalZpMHBDaWxSUEx4d2llQUtBODAxUzgwX0p4S3ZqOWZjZDRvdVdaUWhFcERPVnN2Rzg2RzFJeWk0cWNEcXlmTWlCTkNwZTB3bFluSzlrM0I0MkNZdExwVWxZS3h6cnJSOXdEZDBrMm9USHZR?o…
AstraZeneca Stock: What We Thought of Earnings - Morningstar
<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxOMExKMjU4a1R3U19PRXRlMjc4SjNMRm9LTG1VTzZxNVhnMzV2MGM3RXJGc3NLUmlrZWxTbWtDYkNZVUMtOEtMZkJYN3A5NHpSQlVwemFHWWRsd1Z4NUVHdVF2eFo4Q0JyRkFKWmkyV2ZYc19IaU41S2llU09WTGxKNElGT0RYWXhIeTVYcF…
AstraZeneca slides after reports of Bristol Myers merger talks leave analysts 'perplexed' - CNBC
<a href="https://news.google.com/rss/articles/CBMiigFBVV95cUxNVS1KQnBkQTRhaDZnVk5GVWQ0ajd6dzBGUmVhVHBfeXUtcEF1bURTV0JaanVLQzRrcU50Qm95X2NGcV95NDVWV0g1ZXlQaEtLdGtzVU5UbmlsY19SWGZPcjAyQVdlSUxJSVZjaVRadnFvRWhYTk5BaXFMYkpVVFo1aXI3T3ZKZXZYQ2fSAY…
ASTRAZEN — Frequently Asked Questions
What is the current share price of AstraZeneca Pharma India Limited (ASTRAZEN)?
As of 2026-09-08 04:53 IST, AstraZeneca Pharma India Limited (ASTRAZEN) trades at ₹6,944.00 on NSE. Its 52-week range is ₹6,868.00 to ₹9,783.79.
What is the market capitalisation of ASTRAZEN?
AstraZeneca Pharma India Limited (ASTRAZEN) has a market capitalisation of ₹17,360.00 Cr on NSE.
What is the P/E ratio of ASTRAZEN?
ASTRAZEN trades at a trailing price-to-earnings (P/E) ratio of 92.59. The industry average P/E is 41.64. Its price-to-book (P/B) ratio is 23.46.
Does ASTRAZEN pay a dividend?
AstraZeneca Pharma India Limited (ASTRAZEN) currently offers a dividend yield of 0.45%.
What is the return on equity (ROE) of ASTRAZEN?
ASTRAZEN has a return on equity (ROE) of 21.49%. Its return on capital employed (ROCE) is 25.48%.
Is ASTRAZEN a good stock to buy?
This page provides a data-driven analysis of AstraZeneca Pharma India Limited (ASTRAZEN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.